A Network Approach for HIV-1 Drug Resistance Prevention

被引：0

作者：

Harada, Kouji ^{[1
]}

Ishida, Yoshiteru ^{[1
]}

机构：

[1] Toyohashi Univ Technol, Toyohashi, Aichi 4418585, Japan

来源：

KNOWLEDGE-BASED AND INTELLIGENT INFORMATION AND ENGINEERING SYSTEMS, PT II, PROCEEDINGS | 2009年 / 5712卷

关键词：

COMBINATIONS;

D O I：

暂无

中图分类号：

TP18 [人工智能理论];

学科分类号：

081104 ; 0812 ; 0835 ; 1405 ;

摘要：

In AIDS treatments, it is an imperative problem to reduce the risk of the drug resistance. The previous study discussed which HIV-1 gene products are an idea,l drug target not to develop drug resistance by applying some ideas of the graph theory, and suggested that the drug resistance would not develop if the drug target molecule functions as "hub" in a chemical network where HIV-1 gene products interact directly or indirectly with intracellular agents in a HIV-1. host cell. The present study fortifies this suggestion in mathematical framework. The study develops the expression for a probability of drug resistance developing over the two different types: non-hub and hub of drug targets, and demonstrates that the hub drug target is more favorable for the drug resistance prevention than the non-hub one.

引用

页码：782 / 788

页数：7

共 18 条

[1] Error and attack tolerance of complex networks [J].

Albert, R ;

Jeong, H ;

Barabási, AL .

NATURE, 2000, 406 (6794) :378-382

[2]

[Anonymous], GLOBAL HIV AIDS MED

[3] Network biology:: Understanding the cell's functional organization [J].

Barabási, AL ;

Oltvai, ZN .

NATURE REVIEWS GENETICS, 2004, 5 (02) :101-U15

[4] Strategies for optimizing combinations of molecularly targeted anticancer agents [J].

Dancey, Janet E. ;

Chen, Helen X. .

NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (08) :649-659

[5] Escherichia coli mutants lacking all possible combinations of eight penicillin binding proteins: Viability, characteristics, and implications for peptidoglycan synthesis [J].

Denome, SA ;

Elf, PK ;

Henderson, TA ;

Nelson, DE ;

Young, KD .

JOURNAL OF BACTERIOLOGY, 1999, 181 (13) :3981-3993

[6] Functional profiling of the Saccharomyces cerevisiae genome [J].

Giaever, G ;

Chu, AM ;

Ni, L ;

Connelly, C ;

Riles, L ;

Véronneau, S ;

Dow, S ;

Lucau-Danila, A ;

Anderson, K ;

André, B ;

Arkin, AP ;

Astromoff, A ;

El Bakkoury, M ;

Bangham, R ;

Benito, R ;

Brachat, S ;

Campanaro, S ;

Curtiss, M ;

Davis, K ;

Deutschbauer, A ;

Entian, KD ;

Flaherty, P ;

Foury, F ;

Garfinkel, DJ ;

Gerstein, M ;

Gotte, D ;

Güldener, U ;

Hegemann, JH ;

Hempel, S ;

Herman, Z ;

Jaramillo, DF ;

Kelly, DE ;

Kelly, SL ;

Kötter, P ;

LaBonte, D ;

Lamb, DC ;

Lan, N ;

Liang, H ;

Liao, H ;

Liu, L ;

Luo, CY ;

Lussier, M ;

Mao, R ;

Menard, P ;

Ooi, SL ;

Revuelta, JL ;

Roberts, CJ ;

Rose, M ;

Ross-Macdonald, P ;

Scherens, B .

NATURE, 2002, 418 (6896) :387-391

[7] Evidence for dynamically organized modularity in the yeast protein-protein interaction network [J].

Han, JDJ ;

Bertin, N ;

Hao, T ;

Goldberg, DS ;

Berriz, GF ;

Zhang, LV ;

Dupuy, D ;

Walhout, AJM ;

Cusick, ME ;

Roth, FP ;

Vidal, M .

NATURE, 2004, 430 (6995) :88-93

[8]

HARADA K, 2009, P AROB 14, P522

[9] Network pharmacology: the next paradigm in drug discovery [J].

Hopkins, Andrew L. .

NATURE CHEMICAL BIOLOGY, 2008, 4 (11) :682-690

[10]

HWANG WC, CLIN PHARMACOL THER, DOI DOI 10.1038/CLPT.2008.12

← 1 2 →